Vivos Therapeutics (NASDAQ:VVOS) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Vivos Therapeutics (NASDAQ:VVOS) in a report published on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $7.00 price target on the stock. HC Wainwright also issued estimates for Vivos Therapeutics’ Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($2.00) EPS, Q1 2026 earnings at ($0.38) EPS, Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($1.19) EPS.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 10th. Ascendiant Capital Markets lifted their price target on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Zacks Research downgraded shares of Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.25.

Vivos Therapeutics Stock Down 4.5%

Vivos Therapeutics stock opened at $2.36 on Monday. The firm has a market capitalization of $17.70 million, a P/E ratio of -1.40 and a beta of 6.87. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 1.69. Vivos Therapeutics has a twelve month low of $1.98 and a twelve month high of $7.95. The stock’s fifty day simple moving average is $2.94 and its 200-day simple moving average is $3.51.

Vivos Therapeutics (NASDAQ:VVOS) last released its earnings results on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.01. Vivos Therapeutics had a negative return on equity of 232.76% and a negative net margin of 99.49%.The firm had revenue of $6.78 million during the quarter, compared to analyst estimates of $4.49 million. As a group, equities analysts expect that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Trading of Vivos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VVOS. XTX Topco Ltd purchased a new stake in shares of Vivos Therapeutics during the 2nd quarter worth approximately $65,000. B. Riley Wealth Advisors Inc. acquired a new stake in Vivos Therapeutics during the 2nd quarter worth $220,000. Finally, Connective Capital Management LLC purchased a new stake in Vivos Therapeutics in the third quarter valued at $620,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.